Render Target: STATIC
Render Timestamp: 2024-10-08T10:42:25.918Z
Commit: f04ddd7fea9fb3592f59f61482fcb94610d25cbe
1% for the planet logo
PDP - Template Name: Chemical Modulators
PDP - Template ID: *******c501c72

Cycloheximide #2112

    Product Information

    Product Usage Information

    Cycloheximide is supplied as a lyophilized powder. For a 10 mg/ml stock, carefully weigh out and reconstitute 50 mg in 5 ml DMSO or EtOH. Working concentrations and length of treatments vary depending on the desired effect, but it is typically used at 5-50 µg/ml for 4-24 hours. Soluble in DMSO, EtOH, or MeOH.


    Wear personal protective equipment. Do not empty product into drains. Do not handle until all safety precautions have been read and understood.

    Safety Information: Cycloheximide is suspected of causing genetic defects. It may cause adverse reproductive effects - such as birth defect, miscarriages, or infertility. Avoid contact during pregnancy and while nursing. If exposed or concerned, get medical advice. See Safety Data Sheet (SDS).

    Storage

    Store lyophilized or in solution at -20ºC, desiccated. Protect from light. In lyophilized form, the chemical is stable for 24 months. Once in solution, use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

    Product Description

    Molecular Weight 281.3 g/mol
    Purity >90%
    Molecular Formula C15H23NO4
    CAS 66-81-9
    Solubility Soluble in DMSO at 25mg/ml and in H2O at 20mg/ml.

    Background

    Cycloheximide is a protein synthesis inhibitor in eukaryotes. Although its precise mechanism of action has yet to be fully elucidated, it has been shown to inhibit translation elongation through binding to the E-site of the 60S ribosomal unit and interfering with deacetylated tRNA (1-3). Although not all cell types are equally sensitive to the apoptosis-inducing effects of cycloheximide, it has been shown to induce cell death in T cells through a FADD-dependent mechanism (4). In addition, cycloheximide and Tumor Necrosis Factor possess a synergistic cytotoxicity (5,6), and consequently they are routinely used together to induce cell death. Investigators have demonstrated that cycloheximide blocks bortezomib-stimulated protein ubiquitination (7).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.